JMT101

Phase 3Small molecule

CCSPC Megalith Biopharmaceutical Co.,Ltd.

JMT101 is one of 98 small molecule programs targeting Esophageal Squamous Cell Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal Squamous Cell CarcinomaActive, not recruiting

Metastatic Colorectal CancerActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Esophageal Squamous Cell CarcinomaPhase 1

Active, not recruiting

Metastatic Colorectal CancerPhase 3

Active, not recruiting

Non-Small Cell Lung CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

JMT101

CCSPC Megalith Biopharmaceutical Co.,Ltd.

Phase 3

6 2

Yervoy

Bristol-Myers Squibb

Preclinical

31 3

Gemzar

GGynecologic Oncology Group

Preclinical

72 4

PORTRAZZA

Eli Lilly

Preclinical

8 5

Lenvima

Eisai

Preclinical

6 6

Imjudo

AstraZeneca

Preclinical

5 7

Vizimpro

Pfizer

Preclinical

4 8

Gilotrif

Boehringer Ingelheim

Preclinical

12 9

Ofev

Boehringer Ingelheim

Preclinical

7 10

PD-1 Inhibitor

Johnson & Johnson

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Non-Small Cell Lung Cancer

NCT06391944

Q2 2027

Phase 2Not yet recruiting

Nasopharyngeal Cancer

NCT06892431

Q4 2027

Phase 2/3Not yet recruiting

Non-Small Cell Lung Cancer

NCT06319313

Q1 2028

Phase 3Not yet recruiting

Non-Small Cell Lung Cancer

NCT06380348

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer6 trials

Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer

Unknown status·SShanghai JMT-Bio Inc.·Phase 1·NCT04448379·48 enrolled

Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer

Unknown status·SShanghai JMT-Bio Inc.·Phase 2·NCT05132777·155 enrolled

Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer

Not yet recruiting·SShanghai JMT-Bio Inc.·Phase 2/3·NCT06319313·534 enrolled

Show 3 more trials

JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

Not yet recruiting·SShanghai JMT-Bio Inc.·Phase 3·NCT06380348·398 enrolled

JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations

Active, not recruiting·SShanghai JMT-Bio Inc.·Phase 2·NCT06391944·161 enrolled

A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations

Recruiting·SShanghai JMT-Bio Inc.·Phase 3·NCT06735391·516 enrolled

Metastatic Colorectal Cancer2 trials

A Study of JMT101 in Patients With Metastatic Colorectal Cancer

Unknown status·SShanghai JMT-Bio Inc.·Phase 2·NCT06089330·102 enrolled

The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer

Not yet recruiting·SShanghai JMT-Bio Inc.·Phase 3·NCT07134205·252 enrolled

Nasopharyngeal Cancer1 trial

JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer

Not yet recruiting·SShanghai JMT-Bio Inc.·Phase 2·NCT06892431·150 enrolled

HNSCC1 trial

SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCC

Not yet recruiting·CCSPC Megalith Biopharmaceutical Co.,Ltd.·Phase 2·NCT06989671·430 enrolled

Esophageal Squamous Cell Carcinoma1 trial

JMT101 Combined With Afatinib in Patients With Advanced Esophageal Squamous Cell Carcinoma After Standard Therapy

Unknown status·PPeking University·Phase 1·NCT05164848·50 enrolled

1 more indication

Advanced Solid Tumor1 trial

Efficacy and Safety of JMT101 in Patients With Advanced Solid Tumor

Unknown status·SShanghai JMT-Bio Inc.·Phase 1·NCT04689100·259 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for JMT101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — JMT101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for JMT101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CSPC Megalith Biopharmaceutical Co.,Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CCSPC Megalith Biopharmaceutical Co.,Ltd.

JMT101

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q4 2027

Q1 2028

Trials by Indication[1]

Non-Small Cell Lung Cancer6 trials

Metastatic Colorectal Cancer2 trials

Nasopharyngeal Cancer1 trial

HNSCC1 trial

Esophageal Squamous Cell Carcinoma1 trial

Advanced Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News